<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Calibri Light";
panose-1:2 15 3 2 2 2 4 3 2 4;}
/* Style Definitions */
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
p.xmsonormal, li.xmsonormal, div.xmsonormal
{mso-style-name:x_msonormal;
margin:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.xxmsonormal, li.xxmsonormal, div.xxmsonormal
{mso-style-name:x_xmsonormal;
margin:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.xxxxxmsonormal, li.xxxxxmsonormal, div.xxxxxmsonormal
{mso-style-name:x_xxxxmsonormal;
margin:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple" style="word-wrap:break-word">
<div class="WordSection1">
<div>
<div>
<div>
<p class="xmsonormal"><span style="font-size:12.0pt">Hi all, </span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:12.0pt"> </span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:12.0pt">NASTAD DUH will be hosting the
<i>Beyond the Alerts: Practical Guidance for Responding to Xylazine</i> webinar on
<b>Tuesday, February 21, 3:00-4:30 PM EST.</b> Please see below for more information, share with your networks, and<span style="color:black"> </span><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnastad.zoom.us%2Fmeeting%2Fregister%2FtZEqd-ivrTMvG9d0QwIQaWBIHSzHg13bSlCL&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332488098%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=yQou3Icypju%2B9D2nyX2vxZOO9Mb%2FRXVD7rXJpC%2Fk%2BCQ%3D&reserved=0">register
here</a>. </span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:12.0pt"> </span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:12.0pt">Thanks, </span><o:p></o:p></p>
<div>
<p class="xmsonormal"><b><span style="font-size:14.0pt;font-family:"Calibri Light",sans-serif;color:#008FC5;letter-spacing:.3pt">Elika Upadhyay</span></b>
<b><span style="color:#D14414"><br>
</span></b><span style="color:#404040">Senior Associate, Drug User Health</span><o:p></o:p></p>
<p class="xmsonormal"><span style="color:#404040">Pronouns: She/Her/Hers</span><o:p></o:p></p>
<p class="xmsonormal"><span style="color:#404040">202.897.0108 (o) |</span><span style="color:#008FC5">
</span><a href="mailto:eupadhyay@NASTAD.org">eupadhyay@NASTAD.org</a><span style="color:#1F497D">
<br>
</span><b><span style="color:#008FC5;letter-spacing:.3pt">NASTAD</span></b><o:p></o:p></p>
</div>
<p class="xmsonormal"><span style="font-size:12.0pt"> </span><o:p></o:p></p>
<div>
<div style="border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in 0in 0in">
<p class="xmsonormal"><b>From:</b> Stephen Lee <<a href="mailto:stephenlee@nastad.org">stephenlee@nastad.org</a>>
<br>
<b>Sent:</b> Wednesday, February 8, 2023 1:53 PM<br>
<b>To:</b> Billy Golden <<a href="mailto:bgolden@nastad.org">bgolden@nastad.org</a>><br>
<b>Subject:</b> February 21 Webinar: Beyond the Alerts: Practical Guidance for Responding to Xylazine<o:p></o:p></p>
</div>
</div>
<p class="xmsonormal"> <o:p></o:p></p>
<div>
<div>
<p class="xxmsonormal" align="center" style="text-align:center"><span style="font-size:13.0pt"><img border="0" width="288" height="79" style="width:3.0in;height:.8194in" id="x_x_Picture_x0020_1" src="cid:image001.png@01D93A64.94F14240" alt="A picture containing text, clipart
Description automatically generated"></span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black">February 8, 2023</span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black"> </span><o:p></o:p></p>
<p class="xxmsonormal"><span style="font-size:13.0pt">TO: NASTAD Members </span><o:p></o:p></p>
<p class="xxmsonormal"><span style="font-size:13.0pt">FR: Stephen Lee and Billy Golden </span><o:p></o:p></p>
<p class="xxmsonormal"><span style="font-size:13.0pt">RE: February 21 Webinar<b>:</b> Beyond the Alerts: Practical Guidance for Responding to Xylazine</span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal" style="font-variant-caps:normal;orphans:auto;text-align:start;widows:auto;word-spacing:0px">
<span style="font-size:13.0pt;color:black">Please join NASTAD and partners for a webinar on <b>Tuesday, February 21, 3:00-4:30 PM EST </b>to discuss field-based observations and practices when working with people experiencing health problems related to xylazine
presence in the drug supply. To join the webinar, you may </span><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnastad.zoom.us%2Fmeeting%2Fregister%2FtZEqd-ivrTMvG9d0QwIQaWBIHSzHg13bSlCL&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332488098%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=yQou3Icypju%2B9D2nyX2vxZOO9Mb%2FRXVD7rXJpC%2Fk%2BCQ%3D&reserved=0"><span style="font-size:13.0pt">register
here</span></a><span style="font-size:13.0pt;color:black">. </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black">Jurisdictions are reporting the increased use of the veterinary sedative, xylazine, as an adulterant in the illicit drug supply. Although first documented in the early 2000s in Puerto Rico
and Philadelphia, little guidance exists on how to best respond to related health risks. This webinar focuses on working with people who have xylazine-related wounds, responding to overdoses involving xylazine, and managing withdrawal. Information shared may
be useful for any individuals who are using drugs that may be adulterated with xylazine or for programs that want to share guidance with their direct service staff.</span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black">The webinar will be moderated by Alice Bell, L.C.S.W., the Project Coordinator for Prevention Point Pittsburgh’s Overdose Prevention Project and a co-facilitator of the Opiate Safety and Naloxone
Network. The webinar will feature Jason Beinert, a registered nurse </span><span style="font-size:13.0pt">in<span style="color:black"> Maryland who has been working with people impacted by xylazine in inpatient critical care, outpatient, and community-based
settings. Jason’s work in wound care has focused on teaching people how to best care for xylazine-related wounds. Jason will share his observations and what he has learned and been taught by the people he serves. </span></span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt;color:black"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:13.0pt">For more information about xylazine, please refer to </span><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fharmreduction.org%2Fissues%2Fxylazine%2F&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332488098%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=u2FNeuaaNuT1thfI3cgCkgF2oZSF9zhwWiWb8X1mmxI%3D&reserved=0"><span style="font-size:13.0pt">these
resources</span></a><span style="font-size:13.0pt"> from the </span><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fharmreduction.org%2F&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=CJD9HylaAvSvd4aPe3v5m%2F5C1Ju%2F%2BBpMD4ng3EdmWkM%3D&reserved=0"><span style="font-size:13.0pt">National
Harm Reduction Coalition</span></a><span style="font-size:13.0pt">.</span><o:p></o:p></p>
<p class="xxmsonormal"><span style="font-size:13.0pt"> </span><o:p></o:p></p>
<p class="xxmsonormal"><span style="font-size:13.0pt">Please contact </span><a href="mailto:bgolden@nastad.org" title="bgolden@nastad.org"><span style="font-size:13.0pt">Billy Golden</span></a><span style="font-size:13.0pt"> or
</span><a href="mailto:druguserhealthta@nastad.org" title="mailto:druguserhealthta@nastad.org"><span style="font-size:13.0pt">Drug User Health Team</span></a><span style="font-size:13.0pt"> for further questions.</span><o:p></o:p></p>
<p class="xxmsonormal"> <o:p></o:p></p>
<div>
<div>
<div>
<div>
<p class="xxmsonormal" style="background:white"><b><span style="font-size:14.0pt;font-family:"Calibri Light",sans-serif;color:#008FC5;letter-spacing:.3pt;border:none windowtext 1.0pt;padding:0in">Stephen Lee MD, MBA, DHSM</span><span style="color:#D14414;border:none windowtext 1.0pt;padding:0in"><br>
</span></b><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">Executive Director</span><o:p></o:p></p>
<p class="xxmsonormal" style="background:white"><span style="color:black;border:none windowtext 1.0pt;padding:0in">Pronouns: He/Him/His<br>
</span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">202.897.0028 | </span><span style="color:black"><a href="mailto:slee@NASTAD.org"><span style="border:none windowtext 1.0pt;padding:0in">slee@NASTAD.org</span></a></span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in"><br>
Connect with us: </span><span style="color:black"><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnastad&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=bpzuq1CNqEbUjARKwjVRi63wTZm2ow6GIO95%2FMwbU3c%3D&reserved=0"><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">LinkedIn</span></a></span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in"> | </span><span style="color:black"><a href="https://gcc02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.facebook.com%2FNASTAD&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=Db56qDzz1ewy8mu%2F%2BPHxyNwbvfzd7n5Yv7t%2Bo5aK3Pk%3D&reserved=0"><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">Facebook</span></a></span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in"> | </span><span style="color:black"><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftwitter.com%2FNASTAD&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=eiNjItOGQuBd4xpKDHQS57qavbe70dYbavR7UoT3Vtg%3D&reserved=0"><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">Twitter</span></a></span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in"> | </span><span style="color:black"><a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FNASTAD1992&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=AH98ddx7zWU4lBDjHH59Gx%2F%2F3FWOG%2FCj%2BmnSv2YCYEw%3D&reserved=0"><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">YouTube</span></a></span><span style="color:#1F497D;border:none windowtext 1.0pt;padding:0in"><br>
</span><b><span style="color:#008FC5;letter-spacing:.3pt;border:none windowtext 1.0pt;padding:0in">NASTAD</span></b><span style="color:#008FC5;border:none windowtext 1.0pt;padding:0in"> </span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">| </span><span style="color:#0072C6;border:none windowtext 1.0pt;padding:0in">444
North Capitol Street NW, Suite 339 | Washington, DC 20001</span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">| </span><span style="color:black"><a href="https://gcc02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nastad.org%2F&data=05%7C01%7Calison.goldstein%40odhsoha.oregon.gov%7Cad64b52375174231d0f108db0a091121%7C658e63e88d39499c8f4813adc9452f4c%7C0%7C0%7C638114807332644323%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000%7C%7C%7C&sdata=vXE62EVXRAaWTTNFqF2cEqvAQ4QFp4DL3ZufLO%2BHWSU%3D&reserved=0"><span style="color:#404040;border:none windowtext 1.0pt;padding:0in">NASTAD.org</span></a></span><span style="color:#404040;border:none windowtext 1.0pt;padding:0in"> </span><span style="color:black;border:none windowtext 1.0pt;padding:0in"><br>
</span><span style="font-size:8.0pt;font-family:"Times New Roman",serif;color:#404040;letter-spacing:.3pt;border:none windowtext 1.0pt;padding:0in">This email and any files transmitted with it are confidential and intended solely for the use of the entity to
whom they are addressed. If you received this email in error, please notify the sender.</span><span style="color:black">.</span><o:p></o:p></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</body>
</html>